SpinalCyte Issued Canadian Patent for Spinal Disc Tissue Engineering Technology

By Julie A. Vetalice

SpinalCyte was issued Canadian Patent No. 2,641,170, “Methods and Compositions for Repair of Cartilage using an In Vivo Bioreactor."

The technology, which supports tissue engineering, incorporates a synthetic polymer matrix, a natural hydrogel or a synthetic hydrogel to expose fibroblasts to a mechanical strain using intermittent hydrostatic pressure or fluid shear stress. Other claims provide for growth factors such as bone morphogenetic proteins 2, 4, 6 and 7, transforming growth factor and insulin growth factor.

Source: SpinalCyte, LLC

This adds to SpinalCyte's issued patents in Australia, Japan and the U.S.

In 2014, the company entered a final animal trial with its spinal nucleus replacement technology based on human dermal fibroblasts. Initial animal trials succeeded in regrowing the nucleus and restoring disc height by >80%.

Tags: Patent